Search
retatrutide
Indications:
- investigational weight loss drug
* weight loss at 24 weeks 17% with 12 mg (effectiveness dose-dependent)
Dose:
- start 2-4 mg
- max 12 mg
Adverse effects:
- mostly GI, dose-related, partially mitigated by lower starting dose
Mechanism of action:
- 3 hormone receptor agonist
- glucose-dependent insulinotropic polypeptide receptor (GIPR)
- glucagon-like peptide 1 receptor (GLP-1 receptor)
- glucagon receptor
Interactions
drug adverse effects of hypoglycemic agents
General
glucagon-like peptide 1 (GLP-1) receptor agonist; incretin mimetic; GLP-1 mimetic; GLP-1 agonist; glutide; GLP-1RA
GIP receptor agonist; gastric inhibitory polypeptide receptor agonist; glucose-dependent insulinotropic polypeptide receptor agonist; GIPR agonist
glucagon receptor agonist
References
- Zoler ML
Triple Agonist Retatrutide Hits New Weight-Loss Highs.
Medscape. June 26, 2023
https://www.medscape.com/viewarticle/993714
- Jastreboff AM, Kaplan LM, Frias JP et al
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
N Engl J Med. 2024. Jun 26.
PMID: 37366315
https://www.nejm.org/doi/full/10.1056/NEJMoa2301972